Please check your internet connection and try again.
## Pantoprazole
### Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by irreversibly inhibiting the H+/K+-ATPase enzyme system in gastric parietal cells.
### Primary Indications
* Gastroesophageal reflux disease (GERD)
* Erosive esophagitis healing and maintenance
* Zollinger-Ellison syndrome
* Treatment of duodenal ulcers
* *H. pylori* eradication (in combination with antibiotics)
### Adult Dosing
* **GERD/Erosive Esophagitis:** 40 mg orally or intravenously once daily. May increase to 40 mg twice daily for healing.
* **Maintenance of Healing:** 40 mg orally once daily. Some patients may be maintained on 20 mg orally once daily.
* **Duodenal Ulcers:** 40 mg orally once daily for up to 4 weeks.
* **Zollinger-Ellison Syndrome:** Starting dose 40 mg orally or intravenously twice daily. Doses may be adjusted based on clinical response, with a maximum recommended dose of 240 mg daily (divided doses).
* ***H. pylori* Eradication:** 40 mg orally twice daily for 7-14 days in combination with appropriate antibiotics (e.g., clarithromycin and amoxicillin or clarithromycin and metronidazole).
### Pediatric Dosing
* **GERD/Erosive Esophagitis:**
* **1 month to < 5 years:** 10 mg orally once daily.
* **5 years to < 12 years:** 20 mg orally once daily.
* **12 years to 16 years:** 40 mg orally once daily.
* Dose may be increased for healing erosive esophagitis.
### Dose Adjustments
* **Hepatic Impairment:** Maximum dose of 20 mg orally once daily.
### Contraindications
* Known hypersensitivity to pantoprazole, substituted benzimidazoles, or any component of the formulation.
### Adverse Effects
* **Common:** Headache, diarrhea, nausea, abdominal pain, dizziness, flatulence.
* **Serious/Long-term:**
* *Clostridium difficile*-associated diarrhea.
* Bone fractures (hip, wrist, spine) with prolonged use, especially at higher doses.
* Hypomagnesemia (can be asymptomatic or present with fatigue, muscle cramps, seizures, arrhythmias).
* Vitamin B12 deficiency with prolonged use.
* Possible increased risk of pneumonia.
* Systemic Lupus Erythematosus (SLE).
### Key Drug Interactions
* **Drugs Dependent on Gastric pH for Absorption:** Absorption may be decreased by pantoprazole (e.g., ketoconazole, itraconazole, iron salts, mycophenolate mofetil).
* **CYP2C19 Substrates:** Pantoprazole can inhibit CYP2C19, potentially increasing levels of drugs metabolized by this enzyme (e.g., clopidogrel, citalopram, diazepam).
* **Methotrexate:** Coadministration with PPIs may increase methotrexate levels, potentially leading to toxicity.
### Monitoring
* Electrolytes (especially magnesium, potassium, calcium) with prolonged therapy.
* Bone mineral density in patients at risk for osteoporosis.
* Renal function.
* Signs and symptoms of *Clostridium difficile* infection.
### Clinical Pearls
* Pantoprazole is generally administered 30-60 minutes before a meal.
* Oral formulations should not be crushed or chewed. Tablets can be dispersed in a liquid or mixed with applesauce.
* IV administration should be over at least 15 minutes.
* Long-term PPI use is associated with increased risks, and therapy should be for the shortest duration necessary.
* Consider the risk of rebound acid hypersecretion upon discontinuation; consider gradual tapering.
***
*Disclaimer: This information is intended for healthcare professionals. It is essential to consult the most current prescribing information and relevant clinical guidelines for complete and up-to-date details.*
